Valens Clinical service

Ketamine care

A structured, clinician-supervised pathway for eligible adults, with medical and mental-health review, preparation, monitoring and follow-up integration.

Individualized care

Start with your concerns and goals

Valens begins with a clinical review rather than a preset treatment package. The first visit determines whether this pathway, another Valens service or outside specialty care is the safest next step.

Scope of care

Services available within this pathway

Availability and recommendations depend on clinical findings, clinician scope, facility readiness and applicable requirements.

01

Diagnostic and treatment-history review

02

Medical and psychiatric eligibility assessment

03

Preparation and transportation planning

04

Clinician-supervised administration when approved

05

Physiologic and psychological monitoring

06

Discharge, integration and longitudinal follow-up

Clinical evaluation

What the team reviews

Relevant records are reviewed before repeating testing whenever practical.

What to expect

A clear path from intake to follow-up

  1. 1Complete confidential medical and mental-health screening
  2. 2Meet with the qualified clinician for eligibility review
  3. 3Discuss evidence, off-label status when applicable, risks and alternatives
  4. 4Complete separate treatment-specific informed consent
  5. 5Receive monitored treatment only if approved
  6. 6Follow driving restrictions, discharge guidance and clinical follow-up

Safety and follow-up

Monitoring is part of treatment

Plans are adjusted using response, tolerance, objective findings and patient goals. New symptoms or adverse effects may require pausing treatment or referral.

Blood pressure, pulse, oxygenation and protocol observations

Sedation, dissociation, anxiety, nausea and emergence symptoms

Mood, suicidality, pain or target-symptom response

Misuse risk, urinary symptoms and cognitive concerns

Transportation, recovery and post-treatment safety

Connected specialty resource

KetamineHubs

The connected KetamineHubs resource provides additional eligibility education and access information.

Open specialty website

Common questions

Before you begin

Is ketamine FDA-approved for depression?

Ketamine itself is FDA-approved as an anesthetic, not for psychiatric disorders. Use for depression is off-label. Intranasal esketamine has specific FDA-approved psychiatric indications and separate requirements.

Can ketamine be used at home through Valens?

This page describes clinician-supervised care. At-home compounded ketamine has additional safety concerns because onsite monitoring is absent.

Can I drive after treatment?

No. Patients must follow the clinician’s restriction and arrange responsible transportation. Treatment-day driving and other hazardous activities are prohibited.

Does ketamine replace therapy or ongoing psychiatric care?

No. When used, it should be part of a broader plan that addresses diagnosis, standard treatments, safety, psychotherapy or psychiatric follow-up as appropriate.

Next step

Begin with a secure clinical intake

Do not send medical details through ordinary email. Use the portal so the authorized clinical team can review your request.

Clinical notice: Ketamine for depression or chronic pain may be off-label. Treatment is not guaranteed, is not an emergency service and remains separate from clinical research. Information on this page is educational and does not establish a clinician-patient relationship.

Coordinated Valens network

Move between services without starting over

Your care team can coordinate another Valens pathway when clinically appropriate. Research remains voluntary and uses separate study-specific consent.